China NMPA Drug Inspection - Gansu Hot Spring Biotechnology Co., Ltd. - seaweed

The Gansu Provincial Food and Drug Administration (China) issued an announcement on February 9, 2018, detailing the outcomes of targeted supervision and sampling inspections on traditional Chinese medicine decoction pieces. This initiative aimed to address ongoing concerns regarding product non-compliance, adulteration, counterfeiting, and the use of unauthorized agents like dyes, weight-increasers, or sulfur fumigation.The inspections revealed 17 batches of traditional Chinese medicine decoction pieces from various manufacturers, including Qingyang Yixiang Pharmaceutical Co., Ltd., Zhenyuan County Kangping Pharmaceutical Co., Ltd., and Zhangye Hengli Chinese Medicinal Herb Processing Co., Ltd., to be substandard. Violations, assessed against the *Chinese Pharmacopoeia* (2010 and 2015 editions), encompassed issues with product properties, extractives, identification, content determination, and the presence of sulfur dioxide residue, affecting items such as *Zaocys dhumnades*, *Bletilla striata*, and *Angelica dahurica*.In response, local food and drug administration departments have implemented control measures, including sealing and seizing non-compliant products, and instructed manufacturers to halt sales, cease use, and rectify issues. Moreover, municipal administrations are mandated to investigate and prosecute these illegal activities under Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. They must publicly disclose enforcement results for implicated enterprises within three months and report their findings to the Provincial Bureau, underscoring a commitment to public medication safety.